Modulation of Visually Evoked Potentials by an Antidepressant

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00263133

Enrollment

Registered

2005-12-07

Start date

2005-12-31

Completion date

2006-01-31

Last updated

2007-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, SSRI, Sertraline, synaptic plasticity, visually evoked potentials

Brief summary

12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.

Interventions

DRUGSertraline

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy individuals 18-65 years

Exclusion criteria

* history of affective oder other psyhiatric disorder * severe medical condition * pregnancy or ineffective contraception * active illicit drug use

Design outcomes

Primary

Measure	Time frame
Amplitudes and latencies of early visually evoked potentials.	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026